Advertisements

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Category: press-releasesSource: businesswireindiaJul 28th, 2017

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Category: press-releasesSource: businesswireindiaOct 27th, 2016

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®.....»»

Category: press-releasesSource: businesswireindiaNov 17th, 2016

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®.....»»

Category: press-releasesSource: businesswireindiaSep 16th, 2017

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH.....»»

Category: press-releasesSource: businesswireindiaAug 24th, 2017

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Category: press-releasesSource: businesswireindiaJul 12th, 2017

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases.....»»

Category: press-releasesSource: businesswireindiaMar 20th, 2017

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review.....»»

Category: press-releasesSource: businesswireindiaJan 19th, 2017

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2016

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD.....»»

Category: press-releasesSource: businesswireindiaSep 6th, 2016

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaOct 16th, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma.....»»

Category: press-releasesSource: businesswireindiaJun 27th, 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Category: press-releasesSource: businesswireindiaJun 5th, 2017

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Category: press-releasesSource: prnewswireJan 4th, 2017

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Category: press-releasesSource: prnewswireJan 4th, 2017

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Category: press-releasesSource: prnewswireJan 4th, 2017

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Category: press-releasesSource: businesswireindiaDec 27th, 2016